弥漫性大B细胞淋巴瘤组织NF-κB/p65、Bcl-2和Bax表达及意义
|
摘要
目的探讨弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)组织核转录因子κB(nuclear factor-kappa B,NF-κB)/p65、Bcl-2和Bax蛋白表达及其对临床B症状、国际预后指数(international prognostic index,IPI)得分、临床分期等病理特征和预后的影响。方法组织标本来自于2012年3月至2015年2月我院接受手术治疗的78例DLBCL患者和30例反应增生性淋巴结患者,采用免疫组化方法比较DLBCL患者和反应增生性淋巴结患者淋巴组织NF-κB/p65、Bcl-2和Bax蛋白表达情况,分析它们与病理参数、生存期的关系。结果 DLBCL组织中,NF-κB/p65和Bcl-2阳性率分别为39.74%和51.28%,显著高于反应增生性淋巴结组织(P<0.05),Bax阳性率为32.05%,显著低于反应增生性淋巴结组织(P<0.05);DLBCL组织NF-κB/p65阳性表达与B症状、IPI得分、临床分期有关(P<0.05),Bcl-2阳性表达与IPI得分、临床分期有关(P<0.05),Bax阳性表达与临床分期有关(P<0.05);NF-κB/p65与Bcl-2呈正相关(r=0.53,P<0.05),NF-κB/p65与Bax呈负相关(r=-0.51,P<0.05),Bcl-2与Bax呈负相关(r=-0.62,P<0.05);NF-κB/p65、Bcl-2阳性表达者生存期较短,Bax阳性表达者生存期较长。结论DLBCL组织中NF-κB/p65、Bcl-2高表达,Bax低表达,有助于DLBCL预后评估。
Objective To investigate the expression of NF-κB/p65,Bcl-2 and Bax in diffuse large B cell lymphoma(DLBCL)and the effect on pathological characteristics such as clinical B symptoms,international prognostic index(IPI)scores,clinical stage and prognosis. Methods Tissue samples were obtained from 78 patients with DLBCL and 30 patients with reactive proliferative lymph nodes who underwent surgery from March 2012 to February 2015. Immunohistochemical methods were used to compare lymphoid tissue NF-κB/p65,Bcl-2 and Bax protein expression in patients with DLBCL or reactive proliferative lymph nodes,their relationship with pathological parameters and survival time was analyzed. Results The positive rates of NF-κB/p65 and Bcl-2 in DLBCL tissues were 39.74% and 51.28%,respectively,significantly higher than those in the proliferative lymph node tissues(P<0.05). The positive rate of Bax was 32.05%,significantly lower than that in the reaction hyperplasia lymph node tissue(P<0.05). NB-κB/p65 positive expression in DLBCL was associated with B symptoms,IPI score and clinical stage(P<0.05),Bcl-2 positive expression was associated with IPI score and clinical stage(P<0.05),the positive expression of Bax was associated with clinical stage(P<0.05). NF-κB/p65 was positively correlated with Bcl-2(r = 0.53,P<0.05),NF-κB/p65 was negatively correlated with Bax(r =-0.51,P<0.05),Bcl-2 was negatively correlated with Bax(r =-0.62,P<0.05). The patients with NF-κB/p65,Bcl-2 positive expression had shorter survival time,and patients with Bax positive expression had longer survival time. Conclusion The high expression of NF-κB/p65,Bcl-2 and low expression of Bax in DLBCL tissues contribute to the prognosis evaluation of DLBCL.
Objective To investigate the expression of NF-κB/p65,Bcl-2 and Bax in diffuse large B cell lymphoma(DLBCL)and the effect on pathological characteristics such as clinical B symptoms,international prognostic index(IPI)scores,clinical stage and prognosis. Methods Tissue samples were obtained from 78 patients with DLBCL and 30 patients with reactive proliferative lymph nodes who underwent surgery from March 2012 to February 2015. Immunohistochemical methods were used to compare lymphoid tissue NF-κB/p65,Bcl-2 and Bax protein expression in patients with DLBCL or reactive proliferative lymph nodes,their relationship with pathological parameters and survival time was analyzed. Results The positive rates of NF-κB/p65 and Bcl-2 in DLBCL tissues were 39.74% and 51.28%,respectively,significantly higher than those in the proliferative lymph node tissues(P<0.05). The positive rate of Bax was 32.05%,significantly lower than that in the reaction hyperplasia lymph node tissue(P<0.05). NB-κB/p65 positive expression in DLBCL was associated with B symptoms,IPI score and clinical stage(P<0.05),Bcl-2 positive expression was associated with IPI score and clinical stage(P<0.05),the positive expression of Bax was associated with clinical stage(P<0.05). NF-κB/p65 was positively correlated with Bcl-2(r = 0.53,P<0.05),NF-κB/p65 was negatively correlated with Bax(r =-0.51,P<0.05),Bcl-2 was negatively correlated with Bax(r =-0.62,P<0.05). The patients with NF-κB/p65,Bcl-2 positive expression had shorter survival time,and patients with Bax positive expression had longer survival time. Conclusion The high expression of NF-κB/p65,Bcl-2 and low expression of Bax in DLBCL tissues contribute to the prognosis evaluation of DLBCL.
引文
[1]柴成国,张建军,李宁,等.P53、C-MYC和BCL-6基因异常在弥漫性大B细胞淋巴瘤中的临床意义[J].中国实验血液学杂志,2016,24(1):89-93.
[2]王清云,岑溪南,任汉云.弥漫性大B细胞淋巴瘤的治疗最新进展[J].国际输血及血液学杂志,2017,40(1):51-55.
[3]王辉,邓旭,谢军,等.CMYC、BCL2、BCL6蛋白表达与弥漫性大B细胞淋巴瘤预后关系的研究[J].贵州医药,2018,42(5):518-521.
[4]Kawamoto K,Miyoshi H,Yoshida N,et al.MYCtranslocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma[J].Cancer Science,2016,107(6):853-861.
[5]李亚卓,赵坡.Id2与NF-κB/P65在胃癌中的表达及临床病理意义[J].中华医学杂志,2018,98(11):846-850.
[6]张健,昌军.中和IL-17对博莱霉素诱导的肺纤维化小鼠肺组织Bax/Bcl-2表达的影响[J].医学分子生物学杂志,2016,13(4):218-222.
[7]朱玉侠,赵明星,姜登鸽,等.抑癌基因p53、凋亡抑制基因Bcl-2、促凋亡基因Bax在胃癌及癌前病变中的表达[J].胃肠病学和肝病学杂志,2016,25(9):1040-1043.
[8]Hoppe RT.The non-Hodgkin.s lymphomas:pathology,staging,treatment[J].Current Problems in Cancer,1987,11(6):363-447.
[9]晋龙,眭玉霞,陈志忠,等.凋亡相关蛋白Livin与Caspase-3在弥漫性大B细胞淋巴瘤中的表达及其临床意义[J].中国实验血液学杂志,2017,25(6):1664-1669.
[10]李清平,刘洁,黎艳,等.弥漫大B细胞淋巴瘤组织中Bcl-2、NF-κB、C-myc蛋白表达及临床意义[J].国际检验医学杂志,2017,38(10):1370-1372.
[11]柴成国,张建军,李宁,等.P53、C-MYC和BCL-6基因异常在弥漫性大B细胞淋巴瘤中的临床意义[J].中国实验血液学杂志,2016,24(1):89-93.
[12]糜公仆,王劲,周旭,等.弥漫性大B细胞淋巴瘤中MYC、Bcl-2阳性表达患者的临床特征差异[J].中国医药导报,2016,13(17):25-28.
[13]Kontos CK,Christodoulou MI,Scorilas A.Apoptosisrelated BCL2-family members:key players in chemotherapy[J].Anticancer Agents Med Chem,2014,14(3):353-374.
[14]潘兴飞,张绍全,黄小萍,等.白细胞介素32γ通过活化核转录因子κB通路诱导LX-2细胞表达基质金属蛋白酶9[J].医学分子生物学杂志,2016,13(3):149-152.
[15]Ok CY,Xumonette ZY,Li L,et al.Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2functions[J].Modern Pathology,2015,28(9):1202-1213.
[16]王琳,曹永成,牛爱军,等.胃癌组织中bcl-2、Bax、p16和p53蛋白的表达和意义[J].分子诊断与治疗杂志,2012,4(6):397-399.
[17]朱斌,潘韶英,赵红,等.弥漫性大B细胞淋巴瘤组织中NF-κBp65、P-gp、CYP3A4表达变化及意义[J].山东医药,2014,54(28):68-70.
[18]孟亚红,孙丽华.弥漫性大B细胞淋巴瘤中Bcl-6、Bcl-2和NF-κB的表达及临床意义[J].中国实验诊断学,2017,21(3):510-512.
[19]Gottardo MF,Moreno AM,Ferraris J,et al.Humanin inhibits apoptosis in pituitary tumor cells through several signaling pathways including NF-κB activation[J].J Cell Commun Signal,2017,11(4):1-12.
[20]Johnson M,Robinson M,Marsh C,et al.Expression of Bcl-2,Bax,and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer:relationship with apoptosis and proliferation[J].Prostate,2015,37(4):223-229.
[21]托娅,张和平.乳酸杆菌Lactobacillus casei.Zhang的抗肿瘤作用及机制[J].分子诊断与治疗杂志,2010,2(6):394-399.
[2]王清云,岑溪南,任汉云.弥漫性大B细胞淋巴瘤的治疗最新进展[J].国际输血及血液学杂志,2017,40(1):51-55.
[3]王辉,邓旭,谢军,等.CMYC、BCL2、BCL6蛋白表达与弥漫性大B细胞淋巴瘤预后关系的研究[J].贵州医药,2018,42(5):518-521.
[4]Kawamoto K,Miyoshi H,Yoshida N,et al.MYCtranslocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma[J].Cancer Science,2016,107(6):853-861.
[5]李亚卓,赵坡.Id2与NF-κB/P65在胃癌中的表达及临床病理意义[J].中华医学杂志,2018,98(11):846-850.
[6]张健,昌军.中和IL-17对博莱霉素诱导的肺纤维化小鼠肺组织Bax/Bcl-2表达的影响[J].医学分子生物学杂志,2016,13(4):218-222.
[7]朱玉侠,赵明星,姜登鸽,等.抑癌基因p53、凋亡抑制基因Bcl-2、促凋亡基因Bax在胃癌及癌前病变中的表达[J].胃肠病学和肝病学杂志,2016,25(9):1040-1043.
[8]Hoppe RT.The non-Hodgkin.s lymphomas:pathology,staging,treatment[J].Current Problems in Cancer,1987,11(6):363-447.
[9]晋龙,眭玉霞,陈志忠,等.凋亡相关蛋白Livin与Caspase-3在弥漫性大B细胞淋巴瘤中的表达及其临床意义[J].中国实验血液学杂志,2017,25(6):1664-1669.
[10]李清平,刘洁,黎艳,等.弥漫大B细胞淋巴瘤组织中Bcl-2、NF-κB、C-myc蛋白表达及临床意义[J].国际检验医学杂志,2017,38(10):1370-1372.
[11]柴成国,张建军,李宁,等.P53、C-MYC和BCL-6基因异常在弥漫性大B细胞淋巴瘤中的临床意义[J].中国实验血液学杂志,2016,24(1):89-93.
[12]糜公仆,王劲,周旭,等.弥漫性大B细胞淋巴瘤中MYC、Bcl-2阳性表达患者的临床特征差异[J].中国医药导报,2016,13(17):25-28.
[13]Kontos CK,Christodoulou MI,Scorilas A.Apoptosisrelated BCL2-family members:key players in chemotherapy[J].Anticancer Agents Med Chem,2014,14(3):353-374.
[14]潘兴飞,张绍全,黄小萍,等.白细胞介素32γ通过活化核转录因子κB通路诱导LX-2细胞表达基质金属蛋白酶9[J].医学分子生物学杂志,2016,13(3):149-152.
[15]Ok CY,Xumonette ZY,Li L,et al.Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2functions[J].Modern Pathology,2015,28(9):1202-1213.
[16]王琳,曹永成,牛爱军,等.胃癌组织中bcl-2、Bax、p16和p53蛋白的表达和意义[J].分子诊断与治疗杂志,2012,4(6):397-399.
[17]朱斌,潘韶英,赵红,等.弥漫性大B细胞淋巴瘤组织中NF-κBp65、P-gp、CYP3A4表达变化及意义[J].山东医药,2014,54(28):68-70.
[18]孟亚红,孙丽华.弥漫性大B细胞淋巴瘤中Bcl-6、Bcl-2和NF-κB的表达及临床意义[J].中国实验诊断学,2017,21(3):510-512.
[19]Gottardo MF,Moreno AM,Ferraris J,et al.Humanin inhibits apoptosis in pituitary tumor cells through several signaling pathways including NF-κB activation[J].J Cell Commun Signal,2017,11(4):1-12.
[20]Johnson M,Robinson M,Marsh C,et al.Expression of Bcl-2,Bax,and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer:relationship with apoptosis and proliferation[J].Prostate,2015,37(4):223-229.
[21]托娅,张和平.乳酸杆菌Lactobacillus casei.Zhang的抗肿瘤作用及机制[J].分子诊断与治疗杂志,2010,2(6):394-399.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |